19例脑型血吸虫病临床诊断与治疗

目的 探讨脑型血吸虫病的诊断及治疗。方法回顾性分析2006～2009年我院收治的19例脑型血吸虫病人的临床资料。结果 18例诊断为慢性脑型血吸虫病,1例诊断为急性脑型血吸虫病。全部病例均行内科治疗,8例治愈,5例临床治愈,6例好转。结论 脑型血吸虫病以慢性多见, 内科治疗药物采用吡喹酮效果理想。     

The clinico-immunological characteristics of intestinal schistosomiasis in the Republic of Guinea

The results of clinic and immunological examination of patients with intestinal schistosomiasis at the stage of developed infection in the natives of Guinea are presented. Polymorphism of clinical manifestations was accompanied by diagnostically significant changes in hematological (eosinophilia, increased erythrocyte sedimentation rates) and immunological (higher absolute count of B lymphocytes, IgM levels, amount of T suppressors, lower Tx/Tc ratio) parameters, which, together with the results of parasitological studies, are to be taken into account during the choice of treatment and control over its efficacy.     

A preliminary report on the treatment of intestinal schistosomiasis with oxamniquine.

Oxamniquine proved to be an efficient drug for the treatment of Schistosoma mansoni in adults. The cure rate obtained with a single oral dose of 15 mg/kg was 81.3 per cent. With 15 mg given b.d. for a single day the cure rate was 90 per cent. Post-treatment reduction of egg count was 93.7 and 95 per cent respectively within three months follow-up period. The drug, given by the oral route, was well tolerated, non-toxic, and side-effects were evanescent. Further studies are needed to indicate its use for mass treatment and control of schistosomiasis.     

血吸虫肠病的内镜诊断及病理特征

目的 探讨血吸虫肠病的内镜表现及病理特征,以引起对血吸虫肠病的重视,减少漏诊和误诊.方法 回顾性分析72例血吸虫肠病的大肠镜观察结果并结合病史、组织病理学检查分析血吸虫肠病的内镜诊断和组织学特征.结果 内镜下表现为急性肠炎型16例;慢性肠炎型27例;肠黏膜兼有急性和慢性炎症改变,称之为混合型肠炎,共29例.急性肠炎型的病理特征为大量嗜酸性粒细胞浸润,伴有未钙化的虫卵沉积;慢性型者则有大量淋巴细胞和浆细胞浸润,黏膜下纤维化,伴有已钙化的虫卵沉积;混合型肠炎则兼有上述2型的组织病理学表现.并发结直肠癌5例.在外院误诊为溃疡性结肠炎7例,回盲部肿瘤5例,肠结核2例.结论 血吸虫肠病可分为急性、慢性与混合型结直肠炎3型,混合型血吸虫肠病是区别于急性和慢性血吸虫肠病的又一重要类型.内镜检查加多部位多组织活检发现虫卵沉积是诊断血吸虫肠病的重要方法.     

淋滞疏通方治疗腹水型晚期血吸虫病312 例效果观察

目的 探索使用中药治疗腹水型晚期血吸虫病的效果。方法将312 名腹水型晚期血吸虫病患者随机分成观察组和对照组,每组各156 例。观察组的治疗药物为淋滞疏通方,对照组使用安体舒通和速尿注射液。治疗结束后观察腹水消退和复发情况。结果 312 例患者中,男性患者236 例,女性患者76 例;年龄8~79 岁,平均年龄55.28 岁。治疗后,观察组临床治疗总有效率为93.59%（146/156）,对照组为74.36%（116/156）,两组差异具有统计学意义（χ2=21.435,P<0.05）。观察组腹水消退时间少于对照组患者。观察组患者腹水复发率为27.52%（30/109）,对照组为66.29%（59/89）,两组差异具有统计学意义（χ2=29.760,P<0.05）。观察组患者副反应发生率为7.05%（11/156）,对照组患者副反应发生率为94.86%（148/156）,两组的差异具有统计学意义（χ2=240.717,P<0.05）。结论 淋滞疏通方可作为腹水治疗药物在临床应用。